RGNX has Two Ph1/2 readouts in late 2018: *Wet AMD *Homozygous Familial Hypercholesterolemia (HOFH) Cash runway extends thru 2020. Out-licensed its NAV technology for 20 different potential therapeutics. *put on permanent watchlist